TNFSF11 and hematologic disorder: Denosumab is a monoclonal antibody reduces the osteoclast-mediated bone resorption due to blocking RANKL.[4,14] In animal models of HHM, osteoprotegerin inhibition of RANKL more effectively decreased calcium levels than zoledronic acid.[15] In a study of 31 patients with solid and hematologic malignancies diagnosed with HCM resistant to bisphosponate treatment, 64% of patients had calcium levels <11.5 mg/dl 10 days after denosumab treatment.